Since FLT3 is regulated by HOXA9, and it is frequently highly expressed in AML cells (Figure S4), we evaluated the impact of DOT1L inhibition on the expression of FLT3 and its key downstream components STAT5a and c-MYC (Figure S3A). Here, DOT1L is linked to acute myeloid leukemia.